162 related articles for article (PubMed ID: 18047466)
1. Vitamin A: a drug for prevention of restenosis/reocclusion after percutaneous coronary intervention?
Gidlöf AC; Ocaya P; Krivospitskaya O; Sirsjö A
Clin Sci (Lond); 2008 Jan; 114(1):19-25. PubMed ID: 18047466
[TBL] [Abstract][Full Text] [Related]
2. The paradigm of restenosis following percutaneous transluminal coronary angioplasty.
Preisack MB; Karsch KR
Eur Heart J; 1993 Nov; 14 Suppl I():187-92. PubMed ID: 8293774
[TBL] [Abstract][Full Text] [Related]
3. Preventing restenosis after angioplasty: a multistage approach.
Zargham R
Clin Sci (Lond); 2008 Feb; 114(4):257-64. PubMed ID: 18194134
[TBL] [Abstract][Full Text] [Related]
4. Inflammation and restenosis after percutaneous coronary interventions.
Toutouzas K; Colombo A; Stefanadis C
Eur Heart J; 2004 Oct; 25(19):1679-87. PubMed ID: 15451145
[TBL] [Abstract][Full Text] [Related]
5. Pathogenesis of restenosis. A correlation of clinical observations with cellular responses.
Haudenschild CC
Z Kardiol; 1990; 79 Suppl 3():17-22. PubMed ID: 2099039
[TBL] [Abstract][Full Text] [Related]
6. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions.
Kipshidze N; Dangas G; Tsapenko M; Moses J; Leon MB; Kutryk M; Serruys P
J Am Coll Cardiol; 2004 Aug; 44(4):733-9. PubMed ID: 15312851
[TBL] [Abstract][Full Text] [Related]
7. Preclinical restenosis models: challenges and successes.
Touchard AG; Schwartz RS
Toxicol Pathol; 2006; 34(1):11-8. PubMed ID: 16507539
[TBL] [Abstract][Full Text] [Related]
8. Prevention of restenosis after percutaneous coronary interventions: the medical approach.
Rosanio S; Tocchi M; Patterson C; Runge MS
Thromb Haemost; 1999 Sep; 82 Suppl 1():164-70. PubMed ID: 10695510
[TBL] [Abstract][Full Text] [Related]
9. [Pathophysiology and pathobiochemistry of restenosis].
Höfling B; Gonschior P; Nikol S; Bauriedel G; Welsch U; Nerlich A
Z Kardiol; 1994 May; 83(5):313-8. PubMed ID: 8053238
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of ribonucleotide reductase reduces neointimal formation following balloon injury.
Henry JC; Bonar MM; Kearns PN; Cui H; Mutchler MM; Martin MV; Orsini AR; Elford HL; Bush CA; Zweier JL; Cardounel AJ
J Pharmacol Exp Ther; 2005 Jul; 314(1):70-6. PubMed ID: 15814568
[TBL] [Abstract][Full Text] [Related]
11. Coronary artery restenosis: a paradigm of current treatment approaches.
Kiernan TJ; Kiernan GD; Yan BD
Minerva Cardioangiol; 2009 Feb; 57(1):77-94. PubMed ID: 19202520
[TBL] [Abstract][Full Text] [Related]
12. Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam".
O'Sullivan JF; Martin K; Caplice NM
J Am Coll Cardiol; 2011 Jan; 57(4):383-9. PubMed ID: 21251577
[TBL] [Abstract][Full Text] [Related]
13. Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation-fibrinolysis system.
Lee MS; David EM; Makkar RR; Wilentz JR
J Pathol; 2004 Aug; 203(4):861-70. PubMed ID: 15258987
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological treatment for prevention of restenosis.
Linde J; Strauss BH
Expert Opin Emerg Drugs; 2001 Oct; 6(2):281-302. PubMed ID: 15989527
[TBL] [Abstract][Full Text] [Related]
15. The role of angiotensin receptor 1 blockers in restenosis prevention after percutaneous coronary interventions.
Vassilev D; Doganov A; Gil RJ
Kardiol Pol; 2010 Jan; 68(1):97-101. PubMed ID: 20131196
[No Abstract] [Full Text] [Related]
16. [Pathophysiology of restenosis following percutaneous transluminal coronary angioplasty].
Holm AM; Haunsø S; Hansen PR
Ugeskr Laeger; 1998 Feb; 160(9):1302-6. PubMed ID: 9495077
[TBL] [Abstract][Full Text] [Related]
17. [In vitro balloon treatment of coronary plaque material of the human: effect of dilation time on proliferation of smooth muscle cells].
Voisard R; Dartsch PC; Seitzer U; Grupp C; Hannekum A; Kochs M; Hombach V
Vasa Suppl; 1991; 33():138-9. PubMed ID: 1788646
[TBL] [Abstract][Full Text] [Related]
18. [Is homocysteine a new factor in the pathogenesis of restenosis after percutaneous coronary angioplasty?].
Jankowski P; Bryniarski L; Styczkiewicz K; Bilo G; Curyło A; Kawecka-Jaszcz K
Przegl Lek; 2003; 60(8):527-31. PubMed ID: 14974346
[TBL] [Abstract][Full Text] [Related]
19. The three processes leading to post PTCA restenosis: dependence on the lesion substrate.
Fuster V; Falk E; Fallon JT; Badimon L; Chesebro JH; Badimon JJ
Thromb Haemost; 1995 Jul; 74(1):552-9. PubMed ID: 8578523
[No Abstract] [Full Text] [Related]
20. Peroxisome proliferator-activated receptor gamma; Its role in atherosclerosis and restenosis.
Pakala R; Rha SW; Kuchulakanti PK; Cheneau E; Baffour R; Waksman R
Cardiovasc Radiat Med; 2004; 5(1):44-8. PubMed ID: 15275632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
